{"classes":[{"categories":[{"measurements":[{"comment":"On the basis of DLTs, the MTD of Volasertib administered intravenously on Days 1 and 15 in 28-day cycles in combination with Azacitidine was considered to be less than 200 mg.","groupId":"OG000","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"}],"units":"Participants"}],"description":"This outcome measure presents MTD of Volasertib in Combination with Azacitidine. The MTD was defined as the highest dose level at which Dose Limiting Toxicities (DLTs) were reported in not more than 1 in 6 evaluable patients during Cycle 1.","groups":[{"description":"The patients received Volasertib 200 mg administered by Intravenous Infusion (IV) over 60 minutes on Day 1 and Day 15 of 28-day and Azacitidine 75 mg/m\\^2 administered by subcutaneous injection on days 1-7 of 28 day treatment cycle.","id":"OG000","title":"Volasertib 200 mg"}],"paramType":"NUMBER","populationDescription":"MTD Set: This patient set included all patients in the treated set who were evaluable for MTD determination.","reportingStatus":"POSTED","timeFrame":"Up to 57 days.","title":"Maximum Tolerated Dose of Volasertib","type":"PRIMARY","unitOfMeasure":"mg"}